Grünenthal and Apotex Inc. have announced a new licensing agreement that will grant Apotex the exclusive Canadian rights to Nebido®, a long-acting injectable therapy for the treatment of male hypogonadism. The agreement was announced on Thursday 5 February, 2026. Under the terms of the agreement, Searchlight Pharma, Apotex’s branded medicine division, will pursue marketing authorization and will…
